ARRY 502

Drug Profile

ARRY 502

Alternative Names: ARRY502

Latest Information Update: 17 Oct 2014

Price : $50

At a glance

  • Originator Array BioPharma
  • Class Antiallergics
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma

Highest Development Phases

  • Suspended Allergic asthma

Most Recent Events

  • 17 Oct 2014 Suspended - Phase-II for Allergic asthma in USA (PO)
  • 03 Mar 2014 Efficacy and adverse events data from a phase IIa trial in Allergic asthma presented at the American Academy of Allergy, Asthma and Immunology (AAAAI-2014)
  • 23 Jul 2013 Top-line efficacy & adverse events data from a phase IIa trial in Allergic asthma released by Array BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top